The development of New Delhi metallo-β-lactamase-1 inhibitors since 2018.

New Delhi metallo-β-lactamase-1 (NDM-1) can hydrolyze almost all antibiotics of the β-lactam group, resulting in the generation of multidrug resistant bacteria. Besides its broad hydrolytic activity, pathogens expressing NDM-1 often harbor other antibiotic-resistant genes, further promoting the pervasion of multi-resistant clinical isolates and making clinically available drugs scantier. Despite the urgent need for NDM-1 inhibitors, there is no approved drug in clinic. Here, we summarize NDM-1 inhibitors developed since 2018, classify these compounds by chemical scaffolds, and propose some inconsistencies and notable problems among these studies, which are expected to benefit future research.